<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057380</url>
  </required_header>
  <id_info>
    <org_study_id>7487-CL-0209</org_study_id>
    <secondary_id>2013-004076-34</secondary_id>
    <nct_id>NCT02057380</nct_id>
  </id_info>
  <brief_title>A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial</brief_title>
  <official_title>A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide access to continued treatment for subjects who
      participated in other Astellas sponsored trials and for whom the investigator feels the
      subject may benefit from continued treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2014</start_date>
  <completion_date type="Actual">December 21, 2016</completion_date>
  <primary_completion_date type="Actual">October 14, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A: High dose linsitinib twice daily monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A includes subjects from Protocol OSI-906-301</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: High dose linsitinib BID plus high dose erlotinib QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B includes subjects from Protocol OSI-906-205</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: High dose erlotinib monotherapy once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: High dose linsitinib BID plus weekly paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm D includes subjects from Protocol OSI-906-202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: Highest dose linsitinib intermittent once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: Paclitaxel alone weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm F includes subjects from Protocol OSI-906-202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: Lowest dose linsitinib twice daily + low dose erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm G includes subjects from Protocol OSI-906-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H: high dose linsitinib twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I: highest dose linsitinib once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J: Low dose linsitinib 2x daily+bortezomib &amp; dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>includes subjects from protocol MM-001; Days 1, 4, 8 &amp; 11 (cycles 1-8) and Days 1, 8, 15 &amp; 22 (cycles 9+)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K: med. dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>includes subjects from protocol MM-001; Days 1, 4, 8 &amp; 11 (cycles 1-8) and Days 1, 8, 15 &amp; 22 (cycles 9+)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm L: high dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>includes subjects from protocol MM-001; Days 1, 4, 8 &amp; 11 (cycles 1-8) and Days 1, 8, 15 &amp; 22 (cycles 9+)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linsitinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm B: High dose linsitinib BID plus high dose erlotinib QD</arm_group_label>
    <arm_group_label>Arm A: High dose linsitinib twice daily monotherapy</arm_group_label>
    <arm_group_label>Arm H: high dose linsitinib twice daily</arm_group_label>
    <arm_group_label>Arm K: med. dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_label>Arm L: high dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_label>Arm E: Highest dose linsitinib intermittent once daily</arm_group_label>
    <arm_group_label>Arm I: highest dose linsitinib once daily</arm_group_label>
    <arm_group_label>Arm D: High dose linsitinib BID plus weekly paclitaxel</arm_group_label>
    <arm_group_label>Arm G: Lowest dose linsitinib twice daily + low dose erlotinib</arm_group_label>
    <arm_group_label>Arm J: Low dose linsitinib 2x daily+bortezomib &amp; dexamethasone</arm_group_label>
    <other_name>OSI-906</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm B: High dose linsitinib BID plus high dose erlotinib QD</arm_group_label>
    <arm_group_label>Arm C: High dose erlotinib monotherapy once daily</arm_group_label>
    <arm_group_label>Arm G: Lowest dose linsitinib twice daily + low dose erlotinib</arm_group_label>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Arm E: Highest dose linsitinib intermittent once daily</arm_group_label>
    <arm_group_label>Arm D: High dose linsitinib BID plus weekly paclitaxel</arm_group_label>
    <arm_group_label>Arm F: Paclitaxel alone weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Subcutaneous or IV</description>
    <arm_group_label>Arm K: med. dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_label>Arm L: high dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_label>Arm J: Low dose linsitinib 2x daily+bortezomib &amp; dexamethasone</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>IV, Oral</description>
    <arm_group_label>Arm K: med. dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_label>Arm L: high dose linsitinib 2x daily+bortezomib&amp;dexamethasone</arm_group_label>
    <arm_group_label>Arm J: Low dose linsitinib 2x daily+bortezomib &amp; dexamethasone</arm_group_label>
    <other_name>Maxidex</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Ozurdex</other_name>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must currently be participating in an Astellas sponsored linsitinib trial that
             has ended with respect to the overall study analysis.

          -  Subject must not have met criteria for discontinuation or have progressed on the
             current linsitinib study in which they are participating.

          -  Subject must be deriving benefit from continued treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10004</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0987</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10006</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10002</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10008</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10001</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BR55005</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42001</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49002</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49001</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001</name>
      <address>
        <city>Szczecin</city>
        <state>Zachodniopomorskie</state>
        <zip>70-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SG65002</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH66003</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <disposition_first_submitted>October 2, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 6, 2017</disposition_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>Linsitinib</keyword>
  <keyword>OSI-774</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Tarceva</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>OSI-906</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

